Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Calithera Biosciences, Inc clinical trials
The registry lists 29 studies whose lead sponsor is Calithera Biosciences, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 4, 2023.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Calithera Biosciences, Inc.
- Calithera Biosciences, Inc29 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03428217Phase 2
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2
- NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) TrialTerminatedNCT04698681
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedNCT02049957Phase 2
- A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnNCT03338881Phase 1
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesCompletedNCT02000934Phase 1
- Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT02323113Phase 1/2
- Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyCompletedNCT02756364Phase 2
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological MalignanciesTerminatedNCT03370302Phase 1
- A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedNCT03238651Phase 1
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03123393Phase 2
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnNCT03772288Phase 1
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnNCT03359733Phase 1
- Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid TumorsCompletedNCT02197572Phase 1
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)CompletedNCT03057600Phase 2
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTerminatedNCT04265534Phase 2
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsCompletedNCT03965845Phase 1/2
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)CompletedNCT03163667Phase 2
- Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedNCT02071862Phase 1
- Study to Evaluate the Safety of CB-280 in Patients With Cystic FibrosisCompletedNCT04279769Phase 1
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedNCT03875313Phase 1/2
- Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy SubjectsCompletedNCT04540965Phase 1
- Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult SubjectsCompletedNCT04607512Phase 1
- Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedNCT02071888Phase 1
- Study of the Glutaminase Inhibitor CB-839 in LeukemiaCompletedNCT02071927Phase 1
- A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy AdultsCompletedNCT02944435Phase 1